Sayapina M S, Averinova S G, Zacharova T V, Kashkadaeva A V, Shiryaev S V, Poluectova M V, Vorob'eva O A
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 23 Kashirskoe Shosse, Moscow 115478, Russia.
A. Tsyb Medical Radiological Research Centre, Branch of the National Medical Research Radiological Centre of The Ministry of Health of The Russian Federation, 10 Zhukov St., Obninsk, Kaluga 249036, Russia.
Int J Nephrol. 2017;2017:8549502. doi: 10.1155/2017/8549502. Epub 2017 Oct 22.
To study the effectiveness of complex monitoring of the kidney function, based on biochemical and radionuclide methods in patients with metastatic renal cell carcinoma (mRCC).
41 mRCC patients after nephrectomy received nivolumab ( = 23) and interferon- ( = 18) from 2015 to 2017. At baseline and 2 months after, all patients underwent blood chemistry, urinalysis, Rehberg test, and ELISA to determine serum levels of IL-17A, TGF-, and erythropoietin. The monitoring of the renal function and urodynamics by complex renal scintigraphy (CRS) was used for all patients using a dual-detector gamma camera and simultaneous data recording in 2 projections. The interpretation of CRS data used the original SENS CRS technology.
Statistically significant correlations were established between IL-17A, TGF-, and D (excretion rate of 99mTc-technephore from the parenchyma) and Rnfsc (a stable sign of nephrosclerosis), respectively. A significant correlation was established between the parameters of the complex functional monitoring with the prognosis for the risk of renal failure (RF) and efficacy of immunotherapy in mRCC.
All mRCC patients after nephrectomy were recommended to undergo biochemical monitoring with inclusion of TGF- and IL-17A, as well as radionuclide monitoring (CRS) to determine the RF risk at an early stage.
